Furthermore, short drug treatments in the AOM/DSS mouse model also tended to decrease neutrophils (Fig. 4J) and the NLR ratio (Fig. 4K), further strengthening that p53 activation in HSP90-based therapies effectively remodels the intratumoral immune cell composition and promotes immune activation. The gene discussed is HSP90AA1; the disease is infectious otitis media.